All long term care facilities are required to have an effective immunization program that reflect current standards of practice. Receipt of vaccinations is essential to the health and well-being of long-term care residents. Influenza outbreaks place both the residents and staff at risk of infection. If your facility does have an outbreak, the CDC offers the following guidance. Flu Vaccines must be offered to patients October 1st through March 31st. Facilities are encouraged to promote 100% staff participation in flu shots to prevent outbreaks. Got to www.flu.gov for useful information and resources for your Influenza Vaccination Program. The following forms can be used for education, promotion and documentation of your facility’s Immunization Program. CLICK HERE for the CDC Long-Term Care Toolkit for valuable information. INFLUENZA VACCINE INFORMATION SHEET (English) INFLUENZA VACCINE INFORMATION SHEET (Spanish) POSTER/FLYER 65 YEARS+ (English) POSTER/FLYER 65 YEARS+ (Spanish) POSTER/FLYER HEALTHCARE WORKER (English) POSTER/FLYER HEALTHCARE WORKER (Spanish)
One month delay in FDA Release of this season’s Flu Vaccine Every year, the FDA is responsible for the analysis, review and release of every lot of Influenza Vaccine submitted by each manufacturer. This review must be completed to ensure that their product meets the necessary standards required to safely combat the flue virus. With the extensive review process, this year according to the manufacturer’s the FDA is running approximately 3-4 weeks behind schedule, which has affected the timing and release of approved flue vaccine lots to the manufacturers. With the FDA’s slower than expected release of flue vaccines, fewer approved vaccine lots have been released from the manufacturer’s, which is causing a delay in orders. We understand the importance of implementing you vaccination programs but due to the unpredictability of timing this situation, the Centers for Disease Control and Preventions Advisory Committee on Immunization Practices recommends to schedule immunization programs toward the end of October. Be assured that we will keep you informed and as soon as our vaccines are delivered we will send your orders.
Pneumococcal Disease According to F883, Immunizations for pneumococcal pneumonia the requirements have five aspects: The resident is provided education regarding the benefits and potential side effects of the vaccination The facility must offer each resident pneumococcal immunizations unless the immunization is medically contraindicated, ore the resident’s immunization status is current The resident, or resident’s legal representative, has the right to refuse the vaccinations Each eligible resident is administered the pneumococcal vaccine (unless refused or contraindicated or the resident has already been immunized) The facility must document that education was provided and that the resident either received the vaccine or, if not received, that the vaccine was refused or medically contraindicated or the resident had already been immunized Make sure your facility policy includes all five requirements and that the resident’s medical record documents patient education, offering the vaccine, administering the vaccine. Two pneumococcal vaccines are recommended for adults: PCV13, Prevnar13 and PPSV23, Pneumovax 23. One dose of PCV13 is recommended for adults 65 years and older who have not previously received PCV13. For patients who have not received any pneumococcal vaccine or with unknown vaccination history, give 1 dose of PCV13, and administer 1 dose of PPSV23 at least 1 year later. Once a dose of PPSV23 is given at age 65 or older, no additional doses of PPSV23 should be
F 883 Guidance to Surveyors 483.80(d) Influenza and pneumococcal immunizations The intent of this regulation is to: Minimize the risk o resident acquiring, transmitting, or experiencing complications from influenza an pneumococcal disease by ensuring that each resident: Is informed about the benefits and risks of immunizations: and Has the opportunity to receive the influenza and pneumococcal vaccine(s), unless medically contraindicated, refused or was already immunized Ensure documentation in the resident’s medical record of the information/education provided regarding the benefits and risks of immunization and the administration or the refusal of or medical contraindications to the vaccine(s). Please see the Flu Vaccine Toolkit and Pneumococcal Disease Toolkit for forms and resources.
Question: Is there a difference between pneumococcal vaccines? Answer: Since 2005, Centers for Medicare and Medicaid Services required nursing home to ensure that their residents receive pneumococcal vaccinations. Facilities must offer pneumococcal bacteria: Prevnar, Prevnar13(PCV13), Synflorix and Pneumovax23(PPSV23). There are differences in the way that they are made. Prevnar, Prevnar 13 and Synflorix are conjugate vaccines, while Pneumovax23 is polysaccharide vaccines. Prevnar offers protection against 7 common strains of pneumococcal bacteria, Synflroix against 10 types, Prevnar13 against 13 types and Pneumovax23 against 23 strains of the bacteria. According to recent guidelines, the Advisory Committee in Immunization Practices (ACIP) recommends sequential administration of 2 pneumococcal vaccines for adults over 65 years of age. CMS guidelines recommends the administration of Prevnar 13 followed by Pneumovax23 6 to 12 months later. Those in the 19 to 64 age group are still recommended to receive one dose of Pneumova23 every 5 years. The decision is based on age group and if the patient has been vaccinated previously.